Rodney Jones-Tyson
Rodney Jones-Tyson's purchase track record
Rodney Jones-Tyson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/22/2026 | CSR | $94K | +1.4% | pending | — |
| 5/16/2022 | CSR | $50K | +5.7% | -22.9% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
UBS and Piper Sandler Lower Center Price Targets. UBS and Piper Sandler both maintained Neutral ratings on Centerspace but lowered their price targets to $65 and $56, respectively. These adjustments reflect a more cautious outlook from analysts, though the stock remains supported by its 5.39% dividend yield. The average analyst target stands at $63.43, with a wide range indicating differing views on the company's future performance.
Transaction History
| ASB | ▲ Buy | Grant | 36 | $1K | 9/15/2026 | View on chart |
| CSR | ▲ Buy | Open Market | 1,700 | $94K | 6/22/2026 | View on chart |
| ASB | ▲ Buy | Grant | 38 | $1K | 6/15/2026 | View on chart |
| CSR | ▲ Buy | Option Exercise | 1,446 | $0 | 6/1/2026 | View on chart |
| ASB | ▲ Buy | Grant | 44 | $1K | 3/16/2026 | View on chart |
| ASB | ▲ Buy | Grant | 4,585 | $125K | 2/1/2026 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 12/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 45 | $1K | 9/15/2025 | View on chart |
| ASB | ▲ Buy | Grant | 50 | $1K | 6/16/2025 | View on chart |
| CSR | ▲ Buy | Option Exercise | 1,307 | $0 | 5/20/2025 | View on chart |
| ASB | ▲ Buy | Grant | 51 | $1K | 3/17/2025 | View on chart |
| ASB | ▲ Buy | Grant | 4,972 | $125K | 2/1/2025 | View on chart |
| ASB | ▲ Buy | Grant | 36 | $926 | 12/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 41 | $876 | 9/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 42 | $851 | 6/17/2024 | View on chart |
| CSR | ▲ Buy | Option Exercise | 1,380 | $0 | 5/16/2024 | View on chart |
| ASB | ▲ Buy | Grant | 3,955 | $83K | 4/30/2024 | View on chart |
| CSR | ▲ Buy | Option Exercise | 593 | $0 | 1/17/2024 | View on chart |
| CSR | ▲ Buy | Option Exercise | 856 | $0 | 5/17/2023 | View on chart |
| CSR | ▲ Buy | Open Market | 595 | $50K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Raises ASB Price Target to $35, Maintains Overweight
Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.
Barclays Raises ASB Price Target to $35, Maintains Overweight. Barclays has raised its price target for Associated Banc-Corp to $35 while maintaining an Overweight rating. This move aligns with the broader analyst consensus, where the average target is $34.20. The stock is currently trading near its 52-week high, reflecting recent strength compared to some finance peers. Investors are also awaiting the company's third-quarter earnings report scheduled for late October.